Pharmacogenetic analysis of belimumab fails to identify robust genetic predictors of efficacy in lupus

GlaxoSmithKline (GSK) conducted pharmacogenetic (PGx) analyses to determine whether genetic variants influence response to belimumab treatment in patients with systemic lupus erythematosus (SLE). We conducted an exploratory genome-wide meta-analysis (GWAS) of 10.9 million genetic variants and the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: St Jean, Pamela L., Roth, David A., McCarthy, Linda C., Hughes, Arlene R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613715/
https://www.ncbi.nlm.nih.gov/pubmed/31058715
http://dx.doi.org/10.1097/FPC.0000000000000378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613715/
https://www.ncbi.nlm.nih.gov/pubmed/31058715
http://dx.doi.org/10.1097/FPC.0000000000000378

Ejemplares similares